Literature DB >> 22973045

Double-stranded RNA induces biphasic STAT1 phosphorylation by both type I interferon (IFN)-dependent and type I IFN-independent pathways.

Junichi Dempoya1, Tomoh Matsumiya, Tadaatsu Imaizumi, Ryo Hayakari, Fei Xing, Hidemi Yoshida, Ken Okumura, Kei Satoh.   

Abstract

Upon viral infection, pattern recognition receptors sense viral nucleic acids, leading to the production of type I interferons (IFNs), which initiate antiviral activities. Type I IFNs bind to their cognate receptor, IFNAR, resulting in the activation of signal-transducing activators of transcription 1 (STAT1). Thus, it has long been thought that double-stranded RNA (dsRNA)-induced STAT1 phosphorylation is mediated by the transactivation of type I IFN signaling. Foreign RNA, such as viral RNA, in cells is sensed by the cytoplasmic sensors retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA-5). In this study, we explored the molecular mechanism responsible for STAT1 phosphorylation in response to the sensing of dsRNA by cytosolic RNA sensors. Polyinosinic-poly(C) [poly(I:C)], a synthetic dsRNA that is sensed by both RIG-I and MDA-5, induces STAT1 phosphorylation. We found that the poly(I:C)-induced initial phosphorylation of STAT1 is dependent on the RIG-I pathway and that MDA-5 is not involved in STAT1 phosphorylation. Furthermore, pretreatment of the cells with neutralizing antibody targeting the IFN receptor suppressed the initial STAT1 phosphorylation in response to poly(I:C), suggesting that this initial phosphorylation event is predominantly type I IFN dependent. In contrast, neither the known RIG-I pathway nor type I IFN is involved in the late phosphorylation of STAT1. In addition, poly(I:C) stimulated STAT1 phosphorylation in type I IFN receptor-deficient U5A cells with delayed kinetics. Collectively, our study provides evidence of a comprehensive regulatory mechanism in which dsRNA induces STAT1 phosphorylation, indicating the importance of STAT1 in maintaining very tight regulation of the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22973045      PMCID: PMC3497619          DOI: 10.1128/JVI.01881-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  STATs and gene regulation.

Authors:  J E Darnell
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

Review 2.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.

Authors:  C Schindler; J E Darnell
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

Review 3.  Mx proteins: GTPases involved in the interferon-induced antiviral state.

Authors:  J Pavlovic; A Schröder; A Blank; F Pitossi; P Staeheli
Journal:  Ciba Found Symp       Date:  1993

4.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

5.  Epidermal growth factor-induced growth inhibition requires Stat1 activation.

Authors:  J F Bromberg; Z Fan; C Brown; J Mendelsohn; J E Darnell
Journal:  Cell Growth Differ       Date:  1998-07

6.  Elevated cellular immune responses and interferon-gamma release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis.

Authors:  E Sartono; Y C Kruize; A Kurniawan; P H van der Meide; F Partono; R M Maizels; M Yazdanbakhsh
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

7.  Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.

Authors:  M A Meraz; J M White; K C Sheehan; E A Bach; S J Rodig; A S Dighe; D H Kaplan; J K Riley; A C Greenlund; D Campbell; K Carver-Moore; R N DuBois; R Clark; M Aguet; R D Schreiber
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

Review 8.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Authors:  L M Pfeffer; C A Dinarello; R B Herberman; B R Williams; E C Borden; R Bordens; M R Walter; T L Nagabhushan; P P Trotta; S Pestka
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

9.  Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster.

Authors:  G Lutfalla; S J Holland; E Cinato; D Monneron; J Reboul; N C Rogers; J M Smith; G R Stark; K Gardiner; K E Mogensen
Journal:  EMBO J       Date:  1995-10-16       Impact factor: 11.598

10.  Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection.

Authors:  Andrea K Perry; Edward K Chow; Julia B Goodnough; Wen-Chen Yeh; Genhong Cheng
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more
  18 in total

1.  Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells.

Authors:  Sara Palchetti; Donatella Starace; Paola De Cesaris; Antonio Filippini; Elio Ziparo; Anna Riccioli
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

Review 2.  Host-Intrinsic Interferon Status in Infection and Immunity.

Authors:  Beiyun C Liu; Joseph Sarhan; Alexander Poltorak
Journal:  Trends Mol Med       Date:  2018-07-07       Impact factor: 11.951

Review 3.  Genomic instability and innate immune responses to self-DNA in progeria.

Authors:  Susana Gonzalo; Nuria Coll-Bonfill
Journal:  Geroscience       Date:  2019-07-06       Impact factor: 7.713

4.  ADAR1-mediated RNA editing is required for thymic self-tolerance and inhibition of autoimmunity.

Authors:  Taisuke Nakahama; Yuki Kato; Jung In Kim; Tuangtong Vongpipatana; Yutaka Suzuki; Carl R Walkley; Yukio Kawahara
Journal:  EMBO Rep       Date:  2018-10-25       Impact factor: 8.807

5.  STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.

Authors:  Stephanie P Totten; Young Kyuen Im; Eduardo Cepeda Cañedo; Ouafa Najyb; Alice Nguyen; Steven Hébert; Ryuhjin Ahn; Kyle Lewis; Benjamin Lebeau; Rachel La Selva; Valérie Sabourin; Constanza Martínez; Paul Savage; Hellen Kuasne; Daina Avizonis; Nancy Santos Martínez; Catherine Chabot; Adriana Aguilar-Mahecha; Marie-Line Goulet; Matthew Dankner; Michael Witcher; Kevin Petrecca; Mark Basik; Michael Pollak; Ivan Topisirovic; Rongtuan Lin; Peter M Siegel; Claudia L Kleinman; Morag Park; Julie St-Pierre; Josie Ursini-Siegel
Journal:  Nat Commun       Date:  2021-06-03       Impact factor: 17.694

Review 6.  Tumor suppressor activity of RIG-I.

Authors:  Xian-Yang Li; He-Zhou Guo; Jiang Zhu
Journal:  Mol Cell Oncol       Date:  2014-12-31

7.  Non-Canonical Role of IKKα in the Regulation of STAT1 Phosphorylation in Antiviral Signaling.

Authors:  Fei Xing; Tomoh Matsumiya; Yuko Shiba; Ryo Hayakari; Hidemi Yoshida; Tadaatsu Imaizumi
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

Review 8.  Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis.

Authors:  Ralph A Tripp
Journal:  Immune Netw       Date:  2013-10-26       Impact factor: 6.303

9.  Critical Role of IRF-3 in the Direct Regulation of dsRNA-Induced Retinoic Acid-Inducible Gene-I (RIG-I) Expression.

Authors:  Ryo Hayakari; Tomoh Matsumiya; Fei Xing; Hidemi Yoshida; Makoto Hayakari; Tadaatsu Imaizumi
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

10.  Alteration of Antiviral Signalling by Single Nucleotide Polymorphisms (SNPs) of Mitochondrial Antiviral Signalling Protein (MAVS).

Authors:  Fei Xing; Tomoh Matsumiya; Ryo Hayakari; Hidemi Yoshida; Shogo Kawaguchi; Ippei Takahashi; Shigeyuki Nakaji; Tadaatsu Imaizumi
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.